Cipla receives USFDA nod for nasal spray for treating migraine attacks

Topics Cipla | USFDA | migraine drug

Cipla logo

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks.

The newly approved product is a generic therapeutic equivalent version of GlaxoSmithKline's Imitrex Nasal Spray.

The company has received final approval for its abbreviated new drug application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (USFDA), Cipla said in a regulatory filing.

Quoting IQVIA (IMS Health) data, Cipla said Imitrex Nasal Spray 20mg and its generic equivalents had US sales of approximately USD 53.3 million for the 12-month period ending December 2020.

Shares of Cipla were trading 0.88 per cent higher at Rs 796.45 apiece on BSE.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel